Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with…

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology  The Manila Times

See the original post:

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with...

Related Posts